Bright Begin Period Cash Flow from 2010 to 2024
| DRUG Stock | USD 39.18 1.07 2.81% |
Begin Period Cash Flow | First Reported 2010-12-31 | Previous Quarter 13.4 M | Current Value 8.9 M | Quarterly Volatility 6.4 M |
Check Bright Minds financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Bright Minds' main balance sheet or income statement drivers, such as Depreciation And Amortization of 51.8 K, Interest Expense of 21.6 K or Selling General Administrative of 1.3 M, as well as many indicators such as Price To Sales Ratio of 0.0, Dividend Yield of 0.0 or PTB Ratio of 1.32. Bright financial statements analysis is a perfect complement when working with Bright Minds Valuation or Volatility modules.
Bright | Begin Period Cash Flow |
Latest Bright Minds' Begin Period Cash Flow Growth Pattern
Below is the plot of the Begin Period Cash Flow of Bright Minds Biosciences over the last few years. It is the amount of cash a company has at the beginning of a financial reporting period. It serves as the starting point for calculating the period's cash flow from operations, investing, and financing activities. Bright Minds' Begin Period Cash Flow historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Bright Minds' overall financial position and show how it may be relating to other accounts over time.
| Begin Period Cash Flow | 10 Years Trend |
|
Begin Period Cash Flow |
| Timeline |
Bright Begin Period Cash Flow Regression Statistics
| Arithmetic Mean | 3,682,235 | |
| Geometric Mean | 361,357 | |
| Coefficient Of Variation | 174.88 | |
| Mean Deviation | 5,187,299 | |
| Median | 79,991 | |
| Standard Deviation | 6,439,512 | |
| Sample Variance | 41.5T | |
| Range | 19.7M | |
| R-Value | 0.69 | |
| Mean Square Error | 23.1T | |
| R-Squared | 0.48 | |
| Significance | 0 | |
| Slope | 999,742 | |
| Total Sum of Squares | 580.5T |
Bright Begin Period Cash Flow History
About Bright Minds Financial Statements
Bright Minds stakeholders use historical fundamental indicators, such as Bright Minds' Begin Period Cash Flow, to determine how well the company is positioned to perform in the future. Although Bright Minds investors may analyze each financial statement separately, they are all interrelated. For example, changes in Bright Minds' assets and liabilities are reflected in the revenues and expenses on Bright Minds' income statement, which ultimately affect the company's gains or losses. Understanding these patterns can help in making the right long-term investment decisions in Bright Minds Biosciences. Please read more on our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Begin Period Cash Flow | 13.4 M | 8.9 M |
Currently Active Assets on Macroaxis
When determining whether Bright Minds Biosciences is a strong investment it is important to analyze Bright Minds' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Bright Minds' future performance. For an informed investment choice regarding Bright Stock, refer to the following important reports:Check out the analysis of Bright Minds Correlation against competitors. You can also try the Risk-Return Analysis module to view associations between returns expected from investment and the risk you assume.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Bright Minds. If investors know Bright will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Bright Minds listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.63) | Return On Assets (0.29) | Return On Equity (0.52) |
The market value of Bright Minds Biosciences is measured differently than its book value, which is the value of Bright that is recorded on the company's balance sheet. Investors also form their own opinion of Bright Minds' value that differs from its market value or its book value, called intrinsic value, which is Bright Minds' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Bright Minds' market value can be influenced by many factors that don't directly affect Bright Minds' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Bright Minds' value and its price as these two are different measures arrived at by different means. Investors typically determine if Bright Minds is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Bright Minds' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.